Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Immunol. Jul 27, 2014; 4(2): 122-129
Published online Jul 27, 2014. doi: 10.5411/wji.v4.i2.122
Published online Jul 27, 2014. doi: 10.5411/wji.v4.i2.122
Biologic response modifiers in retinal vasculitis
Sandeep Saxena, Khushboo Srivastav, Retina Service, Department of Ophthalmology, King George’s Medical University, Lucknow 226003, India
Author contributions: Saxena S and Srivastav K solely contributed to this paper.
Correspondence to: Sandeep Saxena, MS, FRCS, Retina Service, Department of Ophthalmology, King George’s Medical University, Chowk, Lucknow 226003, India. sandeepsaxena2020@yahoo.com
Telephone: +91-94-15160528 Fax: +91-94-15160528
Received: March 29, 2014
Revised: May 11, 2014
Accepted: June 18, 2014
Published online: July 27, 2014
Processing time: 119 Days and 23.3 Hours
Revised: May 11, 2014
Accepted: June 18, 2014
Published online: July 27, 2014
Processing time: 119 Days and 23.3 Hours
Core Tip
Core tip: Corticosteroids play a pivotal role in the treatment of intraocular inflammation. Lately, therapy by immunosuppression has taken the center stage for patients with severe intraocular inflammation. However, biologic response modifiers specifically targeting suppression of the immune effector responses have revolutionized the treatment of intraocular inflammation.